Testing tarlatamab with temozolomide for teens and adults with brain and spinal cord tumors
Official title: Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests whether two drugs used together are safe and whether they help against certain brain tumors.
Read our full plain-language summary
What the trial team says
This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts), and to assess the clinical activity of this therapeutic strategy in three parallel, histology-defined cohorts (IDH-mutant glioma, other gliomas, and other CNS tumors). A pre-screening to detect DLL3 expression by IHC on archival tumor sample must be performed before the therapeutic part. Only patients with DLL3 positive tumor on IHC can be enrolled in the therapeutic part. This pre-screening must be optimally performed during the ongoing treatment line i.e. before documented progression to not delay treatment starts at time of progression. Tumor samples (surgery or biopsy specimen) will be sent to a central lab for IHC testing.
Key facts
- Registry number
- NCT07243470
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
Where it is running
This trial lists 12 sites.
-
France
- Institut de Cancérologie de l'Ouest (Angers)
- Centre Hospitalier Universitaire d'Angers (Angers)
- CHU de Bordeaux (Bordeaux)
- Hôpital Saint-André (Bordeaux)
- Hôpital Neurologique Pierre Wertheimer (Bron)
- Centre Oscar Lambret (Lille)
- Centre Léon Bérard (Lyon)
- Hôpital de la Timone - service adulte (Marseille)
- Hôpital de la Timone - service pédiatrie (Marseille)
- Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix (Paris)
- IUCT - Claudius Regaud (Toulouse)
- Institut Gustave Roussy (Villejuif)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.